Tag:
Alimera Sciences
Latest Headlines
Latest Headlines
Alimera taps Quintiles to commercialize Iluvien
Alimera Sciences is facing an uphill battle getting its chronic diabetic macular edema drug on shelves in Europe, and now the company has recruited Quintiles to manage the European launch of Iluvien.
Sanofi names Gary Nabel chief scientific officer for global R&D
Welcome to this week's roundup of hirings and firings throughout the industry. Please send the good word (or the bad) from your shop to Alison Bryant ( email | Twitter ) and we will feature it...
Venrock gets lean and mean with $350M venture fund
Smaller and more tightly focused will be the dominant style for Venrock Associates' new venture fund. The venture group--a busy player in the biotech space --says that it closed its new healthcare
Alimera shares leap on FDA filing for lead program approval
Alpharetta, GA-based Alimera Sciences managed to buck a rough morning on Wall Street as its shares were buoyed by the announcement that the developer has submitted its lead therapy of diabetic
Alimera slashes IPO price while Codexis delivers at low end
The biotech industry got a mixed read on investors' appetite for IPOs yesterday. The biotech Codexis launched its IPO at the low end of its price range on Wednesday, raising $78 million as it
Alimera files $87M IPO
Georgia-based Alimera Sciences is hoping to raise $87 million in an IPO, according to documents the company filed with the SEC today. The developer will offer 6 million shares at a price range of $15
pSivida shares rocket up on late-stage eye drug data
Shares of pSivida rocketed up in overnight trading after investors got wind of the late-stage success of a new ophthalmic drug the biotech is co-developing with Alimera. The company reported that
Alimera refiles $80M IPO as biotech shares slide
Atlanta-based Alimera Sciences has refiled its IPO, upping the ante to $80 million as it tests investors' appetite for biotech stock. Alimera, which is developing new drugs for retina diseases,
Alimera drops $75M IPO
Alimera Sciences has dumped its plans for a $75 million IPO, surprising absolutely no one who has been following the frozen IPO market. The developer has raised $71 million in venture funds since
Alimera Sciences files $75M IPO
Alimera Sciences is braving a badly roiled public market with plans to push a $75 million IPO. The Atlanta-based biotech is developing ophthalmic drugs. Credit Suisse, Citi, Cowen and Co. and Leerink
